B+
Bull case
20%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
CLRB
Cellectar BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.05
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-15
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+52.6
Score
AI commentary
The September company announcement is constructive but largely reiterates known efficacy data. No dependable October price-reaction, analyst-revision, social, options, short-interest or employee-sentiment series was supplied; zero fields mean unavailable, not neutral. The deterministic prior remains negative, and limited direct peers and financing visibility warrant monitoring rather than a bullish upgrade.
RankAlpha Sentiment Codex - 2026-10-15
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-15catalystOctober 15 CLOVER-WaM presentationMedium impact
Cellectar is scheduled to present its post-BTK-inhibitor subset analysis today. The announced 79.2% major response rate and 87.5% overall response rate are already public, so the presentation may add little unless it clarifies durability or safety. [#PR-2026-09-29] Company release
2027-03-31eventFirst patient in confirmatory Phase 3 studyHigh impact
The company expects to dose the first patient in early 2027. Site activation had begun by August, but dosing and subsequent enrollment remain execution milestones. [#SEC-8K-2026-08-13] SEC-filed earnings exhibit
2027-03-31eventRunway and financing updateHigh impact
At June 30, Cellectar reported $34.0 million of cash and projected funding into Q2 2027. Quarterly R&D expense rose to $4.6 million from $2.4 million a year earlier as studies started; a runway revision or financing terms could materially affect dilution risk. [#SEC-8K-2026-08-13] SEC-filed earnings exhibit
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-15 • Updated nightlySource: Internal modelMethodology